This study (ClinicalTrials.gov NCT02110355) assessed the safety, tolerability, pharmacokinetics (PK), and maximum tolerated dose (MTD) of AMG 232 combined with dabrafenib-trametinib or trametinib alone in patients with MM with or without BRAFV600 mutations, respectively, and without prior treatment with BRAF or MEK inhibitors. This evidence concerns the gene BRAF and Miyoshi myopathy.